Compare Moderna, Inc. (MRNA) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vital Farms Inc — how do they compare? Moderna, Inc. trades at $63.68 (market cap $24.18B), while Vital Farms Inc trades at $11.45 (market cap $496.50M). The key difference: Moderna, Inc. is far larger — about 48.7× Vital Farms Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | VITL | |
|---|---|---|
Market Cap | $24.18B | $496.50M |
Sector | Health | Consumer Staples |
52-Week High | $81.80 | $52.41 |
52-Week Low | $22.36 | $8.28 |
Enterprise Value | $20.33B | $583.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Vital Farms (VITL) trades at $11.52, up 2.31% today, amid bearish technical signals and challenging fundamentals. The stock shows oversold conditions with RSI at 29.21, while recent Q2 2026 results revealed a $0.47 per share loss despite beating revenue estimates. The company secured $125 million in financing to navigate industry oversupply pressures and elevated costs affecting profitability.
While analyst consensus remains positive with a $13.00 price target and no sell ratings, near-term headwinds from margin compression and net cash outflows pose significant risks. The stock's valuation appears reasonable with P/E of 11.77 and P/S of 0.67, but investors should monitor execution on cost management and revenue stabilization for sustainable recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
